{
  "docId": "019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "docSlug": "03e126adc7ca1480",
  "documentTitle": "20250114 bayer handout jpm 2025",
  "authorId": "JPMorgan",
  "authorName": "Bayer",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 18,
  "pageCount": 18,
  "prevPage": 17,
  "nextPage": null,
  "slideType": "data_table",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 35,
  "notes": "Includes legend for therapeutic areas, molecule types, and modality icons.",
  "elementsJson": [
    "data_table",
    "icon_grid",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-9cdc5d048fe2/18",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit. 2 Conducted by Merck & Co. 3 Including Precision Cardiovascular, Nephrology & Acute Care. 4 Exclusive commercialization rights acquired for EU markets.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5af54f5a-2396-4ad9-9ab9-b9aebc4fcade",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.48,
        "y": 0.88
      },
      "kind": "legend",
      "text": "Legend for modality icons (Protein Therapeutics, Cell Therapy, Contrast Agent, Genetic Medicine, Radionuclide Therapy, Small Molecule)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c50169d-e02a-4a06-baff-69fe5486fa41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.12,
        "x": 0.85,
        "y": 0.55
      },
      "kind": "legend",
      "text": "Legend for therapeutic areas (Oncology, Cardiovascular, Neurology & Rare Diseases, Immunology, Others) and molecule types (New molecular entity, Life cycle management)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d971a3b9-8f31-48c5-b92d-ebc4a43cb3ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.75,
        "x": 0.08,
        "y": 0.16
      },
      "kind": "table",
      "text": "Pipeline table with columns for Phase I, Phase II, Phase III, and Submissions",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad7b5f0c-daa5-4410-809b-3f86feca3b24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.08,
        "y": 0.08
      },
      "kind": "title",
      "text": "Pharmaceuticals – Pipeline Overview (as of December 11, 2024)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa95366c-302e-4b0d-9dee-ebfb552b55ce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 15,
      "beatId": "335d567b-6530-47e5-af7a-b7d5b8ce502b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The final slides outline the company's plans for growth and profitability",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}